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Antiproteinase 3- and antimyeloperoxidase-associated vasculi- patients with necrotizing crescentic glomerulonephritis
tis. Wegener’s granulomatosis, microscopic polyangiitis, and (NCGN) and microscopic polyangiitis [3]. In these pa-
idiopathic pauci-immune necrotizing crescentic glomerulone- tient categories, proteinase 3 (PR3) and myeloperoxi-phritis (NCGN) are strongly associated with antineutrophil
dase (MPO) were identified as the principle target anti-cytoplasmic autoantibodies (ANCAs) directed against either
proteinase 3 (anti-PR3) or myeloperoxidase (anti-MPO). This gens of C-ANCA and P-ANCA, respectively [3–6]. Later,
has led some investigators to prefer combining these diseases it became apparent that ANCA, predominantly P-ANCA,
under the common heading of ANCA-associated vasculitides. could also be found in patients with a wide range ofHowever, it is increasingly recognized that there are character-
nonvasculitic disorders such as inflammatory bowel dis-istic differences between patients with anti-PR3 and those with
anti-MPO–associated vasculitis. This review focuses on the ease, primary sclerosing cholangitis, autoimmune liver
clinical, histopathologic, and possibly pathophysiologic differ- disease, rheumatoid arthritis, malignancies, and infec-
ences between anti-PR3– and anti-MPO–associated vasculitis. tions [7–18]. ANCAs in these disorders are almost alwaysAlthough there is considerable overlap, the anti-PR3– and
directed against neutrophil constituents other than PR3anti-MPO–associated vasculitides are each characterized by
or MPO or against unknown antigens [17–22]. This indi-particular clinical and histopathological findings. Extrarenal
organ manifestations and respiratory tract granulomas occur cates that sera that are ANCA positive by indirect immu-
more frequently in patients with anti-PR3 than in those with nofluorescence microscopy should be further character-
anti-MPO. Anti-PR3–positive patients with NCGN generally
ized by an antigen-specific assay such as enzyme-linkedhave a more dramatic deterioration of their renal function
immunosorbent assay (ELISA).compared with anti-MPO–positive patients. The term “ANCA-
associated vasculitis” is considered as a useful concept in the In this review, we use the definitions of vasculitis
presence of systemic vasculitis. Likewise, in the presence of adopted by the Chapel Hill consensus conference on the
vasculitis, the terms “anti-PR3–associated vasculitis” and “anti-
nomenclature of systemic vasculitis [23]. In this proposal,MPO–associated vasculitis” are useful concepts.
vasculitides are, in part, classified on the basis of the pre-
dominant size and type of vessel affected. ANCA are
predominantly found in patients with small-vessel vasculi-Antineutrophil cytoplasmic autoantibodies (ANCA)
tis such as Wegener’s granulomatosis and microscopic po-were first described in 1982 by Davies et al in a few
lyangiitis. Small-vessel vasculitis is defined as vasculitispatients with necrotizing glomerulonephritis [1]. In 1985,
van der Woude et al showed that ANCAs producing a that affects vessels smaller than arteries, such as arterioles,
diffuse granular cytoplasmic staining pattern on ethanol- venules, and capillaries. However, small-vessel vasculitis
fixed neutrophils (C-ANCA) are sensitive markers for sometimes also affects arteries, and thus, the vascular dis-
Wegener’s granulomatosis [2]. Subsequently, ANCAs tribution overlaps with that of the medium-vessel and
producing a perinuclear cytoplasmic staining pattern on large-vessel vasculitides. Wegener’s granulomatosis is
ethanol-fixed neutrophils (P-ANCA) were described in defined as granulomatous inflammation involving the re-
spiratory tract and necrotizing vasculitis affecting small-
to medium-sized vessels. Microscopic polyangiitis is de-Key words: ANCA, necrotizing crescentic glomerulonephritis, protein-
ase 3, myloperoxidase, systemic vasculitis, Wegener’s granulomatosis. fined as necrotizing vasculitis with few or no immune
deposits affecting small vessels, but small- and medium-
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manifestations of vasculitis and is then called idiopathic Ceruloplasmin may thus function as a physiological in-
hibitor of MPO [37, 38].pauci-immune NCGN.
Wegener’s granulomatosis, microscopic polyangiitis,
and idiopathic pauci-immune NCGN are strongly associ-
ANTIBODIESated with ANCA directed against either PR3 (anti-PR3)
Autoantibodies against PR3 are directed against mul-or MPO (anti-MPO). This has led some investigators to
tiple epitopes, and serum from different patients may rec-prefer combining these diseases under the common head-
ognize different epitopes [39, 40]. Most antibodies againsting of ANCA-associated vasculitides. However, it is in-
PR3 recognize conformational determinants of the mole-creasingly recognized that there are characteristic and
cule [41]. In addition, anti-PR3 may recognize linearmeaningful differences between patients with anti-PR3
epitopes [40, 42]. These linear epitopes are predomi-and those with anti-MPO–associated vasculitis. This re-
nantly found in the N-terminal part of PR3 and close toview focuses on the clinical, histopathologic, and, possi-
the catalytic site of PR3, which is where a1-antitrypsinbly pathophysiologic differences between anti-PR3– and
binds to PR3 [40]. Antibodies against MPO are alsoanti-MPO–associated vasculitis. We also specify whether
directed against multiple epitopes [43]. The number andthe ANCA specificity has implications for the manage-
localization of epitopes on MPO seem to be restrictedment of individual patients.
[44]. Both conformational and linear epitopes are proba-
bly recognized by anti-MPO–positive sera [42–48].
ANTIGENS Anti-PR3 interferes with the inactivation of PR3 by
Proteinase 3 is a 29 kD serine protease of 228 amino a1-antitrypsin [49–51]. Similarly, anti-MPO has recently
acids that is present in azurophilic granules of neutro- been shown to disturb the inactivation of MPO by cerulo-
phils and peroxidase-positive lysosomes of monocytes plasmin [38].
[5, 24–26]. The enzyme is cationic (isoelectric point 7.9) Both anti-PR3 and anti-MPO of patients with active
and is physiologically inhibited by a1-antitrypsin [27]. ANCA–associated systemic vasculitis are predominantly
PR3 has nonproteolytic antimicrobial activity against of the IgG1 and IgG4 subclasses [52].
bacteria and fungi [28]. In inflammatory conditions, PR3
is released extracellularly, together with other granule
DISEASE ASSOCIATIONSconstituents and oxygen radicals and can degrade colla-
gens, proteoglycans, and other connective tissue constit- Antineutrophil cytoplasmic autoantibodies directed
against either PR3 or MPO are strongly associated withuents [29]. PR3 can cause emphysema when administered
into the bronchial system of hamsters [30]. Circulating Wegener’s granulomatosis, microscopic polyangiitis, and
Churg-Strauss syndrome, conditions that belong to thePR3 is present in sera of patients with active Wegener’s
granulomatosis and polyarteritis nodosa and, at lower group of idiopathic small-vessel vasculitides. The other
members of this group, Henoch-Scho¨nlein purpura, essen-concentrations, in sera of healthy subjects [31].
Myeloperoxidase is also localized in azurophilic gran- tial cryoglobulinemic vasculitis, and cutaneous leukocyto-
clastic vasculitis, are not associated with ANCA [18, 53, 54].ules of neutrophils and lysosomes of monocytes and
makes up almost 5% of the total protein content of the Either anti-MPO or anti-PR3 are also found in the vast
majority of patients with idiopathic pauci-immune NCGN.neutrophil. MPO is a covalently linked dimer with a
molecular weight of about 140 kD and is highly cationic At present, there is no uniform international method-
ology for ANCA testing by either indirect immunofluo-(isoelectric point 11.0) [32]. The perinuclear pattern ob-
served by indirect immunofluorescence microscopy when rescence or ELISA. As a result, the sensitivity and speci-
ficity of C-ANCA/anti-PR3 and P-ANCA/anti-MPO foranti-MPO positive sera are probed on ethanol-fixed neu-
trophils is caused by an artifact during fixation. Ethanol vasculitis may differ from center to center because of
variations in methodology [55, 56]. International stan-fixation disrupts the granule membranes, and the posi-
tively charged MPO moves to the negatively charged dardization of ANCA testing is warranted [57]. Hagen
et al recently showed that ANCA testing by indirectnuclear membrane [32, 33]. MPO catalyzes H2O2-medi-
ated peroxidation of the chloride ion to hypochlorous immunofluorescence in combination with a standardized
antigen-specific ELISA was more accurate than eitheracid [34], which is effective in killing phagocytized bacte-
ria and viruses. In addition, hypochlorous acid and its technique alone [58].
Anti-PR3s are sensitive markers for active Wegener’smetabolites can inactivate protease inhibitors, such as
a1-antitrypsin, in blood and tissues, and thus play a role granulomatosis. The sensitivity depends, apart from dif-
ferences in methodology, on the definition used for thisin tissue degradation in an inflammatory milieu [35].
Circulating MPO has been demonstrated in sera of pa- condition. Three early studies found a 90% sensitivity of
C-ANCA/anti-PR3 for the presence of active extendedtients with NCGN [36]. Recently, ceruloplasmin has been
shown to inactivate the peroxidase activity of MPO [37]. Wegener’s granulomatosis, characterized by the combi-
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nation of granulomatous inflammation of the respiratory alone. Since immunosuppressive treatment is associated
with significant morbidity and mortality [54], histopatho-tract, systemic vasculitis, and pauci-immune NCGN
[59–61]. However, if liberal criteria are used that do not logic proof is desirable in both anti-PR3– and in anti-
MPO–positive patients [54, 69].require histopathologic proof of vasculitis and/or granu-
lomas, for example, the American College of Rheuma- There are now several studies that have compared the
disease associations between patients with anti-PR3 andtologists’ criteria, the sensitivity of C-ANCA (in this
particular study probably mostly anti-PR3) for Wegen- those with anti-MPO [65, 66, 69, 71, 82–85]. There is
general agreement that the majority of patients wither’s granulomatosis is only 28% [62]. Recently, Hagen
et al reported a 64% sensitivity of C-ANCA and a 66% Wegener’s granulomatosis have anti-PR3, whereas most
patients with pauci-immune NCGN have anti-MPO.sensitivity of anti-PR3 for the presence of Wegener’s
granulomatosis [58]. In this study, histologic confirma- Anti-PR3 and anti-MPO are about evenly distributed in
patients with microscopic polyangiitis. It should betion was not obligatory for the diagnosis, and 23% of
patients diagnosed as having Wegener’s granulomatosis noted, however, that the distinction between Wegener’s
granulomatosis and microscopic polyangiitis can be dif-were being treated with immunosuppressive medication
at the time of serum sampling. Most of the patients ficult. Both conditions are closely related and share the
vasculitic involvement of the small-sized vessels. Thewith active extended Wegener’s granulomatosis who are
negative for anti-PR3 have antibodies directed against most important distinction between both conditions is
the nature of the respiratory tract disease and the pres-MPO or, occasionally, elastase [3, 63]. Patients with ac-
tive Wegener’s granulomatosis that is limited to the re- ence of granuloma formation [23, 82]. Upper respiratory
tract involvement in patients with Wegener’s granuloma-spiratory tract have anti-PR3 in about two thirds of the
cases [60]. Anti-PR3s are also found in about 50% of tosis is characterized by an inflammatory and destructive
process with mucosal destruction and sometimes bonypatients diagnosed as having microscopic polyangiitis
[64, 65] and in a minority of patients with idiopathic erosions, septal perforation, and ultimately saddle nose
pauci-immune NCGN [3, 66]. Occasionally, anti-PR3 deformity, whereas upper respiratory tract involvement
have been reported in nonvasculitic disorders [15, 67]. in patients with microscopic polyangiitis is usually rela-
When all of the data are combined, the specificity of tively mild and limited to rhinitis and/or sinusitis. How-
anti-PR3 for the presence of one of the small-vessel ever, clinical and histopathologic data are often inconclu-
vasculitides can be estimated as 98% [68]. sive, and granulomas may be missed in a biopsy because
Within the spectrum of small-vessel vasculitis, anti- of sampling errors or incomplete workup [17, 86, 87].
MPO are found in about 80% of patients with active Thus, the classification of these patients depends in part
idiopathic pauci-immune NCGN [3], in 50% of patients on whether an extensive ear, nose, and throat examina-
with active microscopic polyangiitis [64, 69], and in 70 tion is performed and on the policy to take biopsies
to 80% of patients with the Churg–Strauss syndrome of affected organs. It is appreciated that establishing a
[70–72]. Anti-MPO are also found in other autoimmune precise diagnosis may be difficult in life and that the
disorders, which do not belong to the group of idiopathic diagnosis may change as the disease process evolves [88].
small-vessel vasculitides, such as antiglomerular base- Granulomas are almost exclusively found in anti-PR3–
ment membrane disease, systemic lupus erythematosus, and rarely in anti-MPO–positive patients (vide infra) [3,
and drug-induced glomerulonephritis [73–78]. In addi- 83, 84, 89]. It follows that studies that require granuloma
tion, anti-MPO have occasionally been described in pa- formation for establishing a diagnosis of Wegener’s gran-
tients with a variety of disorders, such as sarcoidosis, ulomatosis will find a much closer association between
IgA nephropathy, atheroembolic disease, and infections this disease and the presence of anti-PR3 than studies
[14, 69, 79–81]. The specificity of anti-MPO for the pres- that do not require this histopathologic hallmark [82].
ence of small-vessel vasculitis varies depending on the
patient and control populations that are studied. In con-
ORGAN MANIFESTATIONSsecutive anti-MPO–positive patients suspected of having
Several studies have compared organ manifestationsvasculitis and/or glomerulonephritis who were not se-
between anti-PR3– and anti-MPO–positive patients [65,lected for the presence of any particular organ involve-
66, 69, 71, 82–85]. These studies show that anti-PR3–ment, the specificity of anti-MPO for any form of vasculi-
and anti-MPO–positive patients show a different diseasetis was 80% [69]. Notably, the specificity of anti-MPO
spectrum. To a great extent, these differences are relatedfor the presence of idiopathic small-vessel vasculitis is
to differences in disease associations as described pre-lower compared with the specificity of anti-PR3 for this
viously in this article. For example, renal-limited diseasegroup of diseases. Demonstrating anti-MPO in a serum
occurs predominantly in patients with anti-MPO [3, 66,sample is definitely not equivalent to the presence of
69, 83], whereas anti-PR3 is more frequent in patientsvasculitis. Treatment should therefore never be insti-
tuted based on the presence of positive test for anti-MPO who have upper and lower respiratory tract involvement
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in combination with renal disease [66, 69, 83, 84]. In Upper and lower respiratory tract disease
addition, anti-PR3–positive patients have some disease Several studies have demonstrated that upper respira-
characteristics that are quantitatively and/or qualita- tory tract involvement is more frequent in anti-PR3–
tively different from those observed in anti-MPO– than in anti-MPO–positive patients with NCGN [66, 69,
positive patients. In general, patients with anti-PR3 have 82–85]. However, anti-MPO and anti-PR3 were found
more widespread extarenal organ involvement com- in equal frequency in patients with glomerulonephritis
pared with anti-MPO–positive patients [69, 83, 85]. In and pulmonary disease [82]. The pattern of lung involve-
consecutive anti-PR3– and anti-MPO–positive patients, ment, however, seems to differ. Pulmonary cavitating
lesions are more frequently present in anti-PR3–positivethe mean number of affected organs was 3.9 and 2.2,
patients [85], whereas alveolar capillaritis with lung hem-respectively [69]. The groups differed strikingly in the
orrhage is found more frequently in anti-MPO–positiveoccurrence of granuloma formation. Detected during
patients [65, 66, 85]. Radiographically, anti-PR3–positivelife, granulomas are predominantly seen in patients with
patients predominantly have nodular or pneumonia-likeanti-PR3 and rarely in patients with anti-MPO [3, 65,
lesions, whereas anti-MPO–positive patients more fre-69, 83, 84]. However, in a postmortem study, some anti-
quently have patchy lung lesions as the consequenceMPO–positive patients were found to have granuloma-
of hemorrhagic capillaritis [96]. These differences aretous inflammation [87]. The following sections review
probably partly explained by the more frequent occur-specific organ manifestations in more detail.
rence of pulmonary granulomas in anti-PR3–positive pa-
tients, which may present as a nodular lesion on theRenal disease
chest x-ray. In anti-PR3– and anti-MPO–positive pa-The prevalence of renal involvement does not differ
tients, alveolar capillaritis or pulmonary hemorrhage oc-between anti-PR3– and anti-MPO–positive patients with
curs in equal frequency [97, 98]. In a retrospective study,
vasculitis and is approximately 75 to 90% [65, 69, 83].
Ter Maaten et al, however, found that acute respiratory
The prevalence of renal involvement may vary during failure caused by alveolar hemorrhage occurred more
the course of the disease. Hoffman et al showed that frequently in anti-PR3– than anti-MPO–positive patients
only 18% of patients with Wegener’s granulomatosis with vasculitis, suggesting a more severe course in anti-
had renal disease at presentation, but 77% of patients PR3–positive patients [99]. At present, this study awaits
subsequently developed frank glomerulonephritis [90]. confirmation.
In many cases, the glomerulonephritis is rapidly progres-
sive and may lead to irreversible renal failure. Histopath- Other organ manifestations
ologically, NCGN is characterized by fibrinoid necrosis In some studies, nervous system involvement was
of the capillary wall with extracapillary proliferation and found more frequently in anti-PR3– than anti-MPO–
crescent formation [91]. Several studies have shown that positive patients with vasculitis [66, 69, 83, 85], but other
the renal lesions associated with anti-PR3 and anti-MPO studies described equal frequencies [65, 82]. Eye involve-
are essentially the same (abstract; Bajema et al, J Am ment has also been reported to occur more frequently
in patients with anti-PR3 than in patients with anti-MPOSoc Nephrol 8:927, 1997) [84, 87]. However, we have
[65, 66, 69, 83]. The prevalence of lesions in other organfound that at the time of diagnosis, anti-PR3–positive
systems frequently involved in ANCA-associated small-patients with NCGN have more active renal lesions, such
vessel vasculitis, such as the skin and the musculoskeletalas glomerular necrosis, whereas anti-MPO–positive pa-
tract, does not differ between patients with anti-PR3 andtients have more chronic lesions, such as glomerular scle-
those with anti-MPO [65, 69, 82, 85].rosis [92]. As shown in Figure 1, this was associated with
a faster deterioration of pretreatment renal function in
patients with anti-PR3 than in those with anti-MPO– DEMOGRAPHIC CHARACTERISTICS
associated renal disease [92]. Some of the anti-MPO– At least four studies have found a preponderance of
positive patients in this study showed a “not so rapidly males in patients with anti-PR3 and of females in patients
progressive” form of glomerulonephritis progressing to with anti-MPO–associated vasculitis [65, 80, 83, 85]. In
uremia over months to years, as has been described by these studies, the male to female ratio ranged from 1.3
several authors [93–95]. These patients may not readily to 1.9 in the anti-PR3 and from 0.3 to 0.8 in the anti-
be recognized as having crescentic glomerulonephritis MPO–positive patient group. ANCA-associated disease
since their renal function deteriorates slowly [94]. In affects primarily older patients, although the age range
addition, we observed that these patients often have only includes pediatric patients as well [82]. We and others
limited extrarenal organ manifestations that may further have found that vasculitis patients with anti-MPO are
contribute to the relatively late recognition of renal vas- older than those with anti-PR3 [65, 69, 85]. In these
studies, the mean age ranged from 45 to 56 years inculitic disease in these patients [92].
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Fig. 1. Doubling of serum creatinine within a
certain time interval prior to the start of treat-
ment in antiproteinase-3 (anti-PR3; j, N 5
38) and antimyeloperoxidase (anti-MPO)–
positive ( , N 5 31) patients with renal
involvement. The numbers on top of the bars
denote the percentage of the total number of
patients with that particular antibody. Re-
printed from Franssen et al [92]; used with
permission from the International Society of
Nephrology.
anti-PR3 and from 57 to 63 years in anti-MPO–positive and do not frequently relapse [64, 103]. Patients with
drug-induced glomerulonephritis can have persistentlypatients. Falk et al found that their study population
of patients with ANCA-associated NCGN had a much high anti-MPO levels years after withdrawal of the drug,
despite full resolution of the symptoms [76]. Recently,higher white to black ratio (7.8) compared with that in
their total network’s renal biopsy population (2.0) [82]. we have found that many, but not all, patients with anti-
MPO–associated NCGN who relapsed or developed
chronic renal failure during follow-up had persistentlyRELATIONSHIP BETWEEN VASCULITIC
high anti-MPO levels after remission had been achieved,DISEASE ACTIVITY AND ANCA TITER
whereas most patients who did not relapse and who had
Various longitudinal studies have demonstrated that a stable renal function during follow-up had persistently
titers of C-ANCA in patients with Wegener’s granulo- low anti-MPO levels [107].
matosis (in these studies directed against PR3) generally
decline during treatment and rise prior to a clinical re-
OUTCOMElapse [59, 100, 101], although this has been disputed by
others [102]. Stegeman et al have shown that relapses Patient and kidney survival of patients with ANCA-
associated vasculitis and/or NCGN have improved dra-occur almost exclusively in those patients with Wegen-
er’s granulomatosis who are persistently or intermit- matically over the past few decades with the advent of
immunosuppressive treatment consisting of corticosteroidstently C-ANCA positive [100]. Thus, persistently ele-
vated or increasing C-ANCA titers should alert the and cyclophosphamide. Three studies found no difference
in either patient or kidney survival between patients withclinician to the possibility of an ensuing relapse. How-
ever, rises of C-ANCA titer are not always followed by anti-PR3– and anti-MPO–associated vasculitis [65, 82,
92]. However, Hogan et al reported that C-ANCA–a clinical relapse of Wegener’s granulomatosis. Prelimi-
nary studies have shown that in the latter case, the rise positive patients with microscopic polyangiitis and idio-
pathic NCGN (excluding patients with Wegener’s granu-in C-ANCA by IIF was not paralleled by a rise in the
IgG3 subclass of anti-PR3, whereas C-ANCA rises that lomatosis) had a higher risk of death as compared with
P-ANCA–positive patients (relative risk of death 3.8were accompanied by rises in the IgG3 subclass of anti-
PR3 were, in almost every case, followed by an exacerba- times greater during a mean follow-up of 2.5 years) [98].
In this study, renal survival did not differ between pa-tion of the disease (abstract; Cohen Tervaert et al, J Am
Soc Nephrol 5:828, 1994). tients with C-ANCA and those with P-ANCA [98]. From
the studies cited previously in this article, patient andCorresponding studies on the value of serial testing
for P-ANCA or anti-MPO are scarce [63, 64, 103–106]. kidney survival in patients with ANCA-associated vascu-
litis at two years after diagnosis can be estimated as 70The available data suggest that patients with systemic
vasculitis associated with anti-MPO often have persis- to 85% and 60 to 75%, respectively.
Several studies have identified prognostic parameterstently positive anti-MPO titers despite disease remission,
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for renal survival in patients with ANCA-associated ANCA-mediated neutrophil activation
NCGN. Renal survival in these patients was inversely Neutrophils are important effector cells of tissue dam-
correlated with serum creatinine prior to start of treat- age in ANCA-associated vasculitis and NCGN [113].
ment [98, 108] and with the percentage of sclerosed glo- Activated neutrophils, releasing lytic enzymes, and free
meruli [93], the degree of tubular atrophy [93, 109], and oxygen radicals are present in affected glomeruli and in
the extent of arterial sclerosis [98] in the renal biopsies
the renal interstitium of patients with ANCA-associated
at diagnosis. In addition, we have found that the degree
NCGN [114]. The number of activated intraglomerularof proteinuria at diagnosis influenced renal survival in
neutrophils correlates with the severity of renal tissueanti-MPO–positive patients. Those patients who devel-
damage, as reflected by serum creatinine levels [114].oped chronic renal failure during follow-up, without
Several studies have shown that ANCAs are capable ofclear signs of relapse, had more proteinuria at diagnosis
activating neutrophils in vitro. Both anti-PR3 and anti-and during the first six months after diagnosis compared
MPO can activate tumor necrosis factor-a (TNF-a)-with patients whose renal function followed a favorable
primed neutrophils, leading to the production of reactivecourse. Patients with a daily proteinuria of less than 2 g
oxygen metabolites and the release of lysosomal proteo-at diagnosis had a better long-term renal survival than
lytic enzymes, including the ANCA antigens themselvesthose with proteinuria of more than 2 g [107]. Compara-
ble studies on the influence of proteinuria on renal survival [114–118]. As such, ANCA-mediated neutrophil activa-
in anti-PR3 positive patients have not been reported. tion may be directly toxic for surrounding cells. It has
About 50% of patients with small-vessel vasculitis will indeed been demonstrated that ANCA can stimulate neu-
have at least one relapse in the four to five years after trophils to damage cultured endothelial cells [119–121].
initial treatment [110]. Two studies have found a higher Previously, we have found that anti-PR3–positive pa-
relapse rate in anti-PR3– than anti-MPO–positive pa- tients have more extensive organ involvement and more
tients [65, 69], although this has been disputed by others active renal lesions in association with a faster deteriora-
(abstract; Nachman et al, J Am Soc Nephrol 8:AO449, tion of their renal function as compared with anti-MPO–
1997). The induction treatment of anti-PR3– and anti- positive patients [92]. In search of an explanation for
MPO–positive patients with small-vessel vasculitis is these differences, we have compared the in vitro neutro-
identical. However, if relapses are indeed less frequent phil-activating capacity of isolated immunoglobulin G
in anti-MPO– than anti-PR3–positive patients, this may
(IgG) fractions from anti-PR3– and anti-MPO–positive
have implications for the duration of the maintenance
patients with active NCGN. We found that IgG fractionsphase of immunosuppressive treatment in anti-MPO–
from anti-PR3–positive patients were more potent acti-versus anti-PR3–positive patients, since there is a ten-
vators of the respiratory burst (Fig. 2) and degranulationdency to tailor treatment to what is minimally required
than IgG fractions from anti-MPO–positive patients. Sig-to prevent relapse to reduce the risk of short- and long-
nificant superoxide release was induced by the majorityterm side effects [54].
(9 of 17) of anti-PR3–positive IgG fractions and by a
minority (3 of 14) of anti-MPO–positive IgG fractions
PATHOPHYSIOLOGIC ROLE OF ANCA: [122]. These observations may be of relevance in view
POSSIBLE DIFFERENCES BETWEEN of the clinical differences between anti-PR3– and anti-
ANTI-PR3 VERSUS ANTI-MPO MPO–positive patients with NCGN.
The association between vasculitic disease activity and
ANCA titer has greatly stimulated research on the possi- Interaction between ANCA and endothelial cells
ble pathophysiological role of ANCA. At present, there Isolated immunoglobulin G fractions from anti-PR3–
is no definitive proof that ANCAs play a causative role and anti-MPO–positive patients can activate endothelial
in the development of systemic vasculitis and/or NCGN.
cells in vitro, resulting in increased expression of adhe-However, experimental data suggest that ANCA and/or
sion molecules, such as E-selectin, vascular cell adhesionANCA antigen-related autoimmune responses are im-
molecule-1, and intercellular adhesion molecule-1, andplicated in the pathophysiology of these diseases. These
increased expression of tissue factor [123–126]. At pres-data have been derived mainly from in vitro studies. In
ent, it is not clear whether endothelial cell activation isaddition, several animal models of ANCA-associated
caused by anti-PR3 and anti-MPO or by anti-endothelialvasculitis have been described [reviewed in 111]. In most
cell antibodies, which can also be found in ANCA-posi-of the models, antibodies against human MPO can be
tive patients with small-vessel vasculitis [127–129]. Dif-induced that show, in part, cross reactivity with rat or
ferences in the capacity to activate endothelial cells be-mouse MPO [111, 112]. At present, there is no animal
tween immunoglobulin G fractions from anti-PR3 andmodel in which antibodies against PR3 recognize rat or
mouse PR3. anti-MPO–positive patients have not been found [129].
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of T-cell activation in vivo and the T-cell reactivity in
vitro may contribute to the differences observed in the
clinical presentation and histopathology of anti-PR3 and
anti-MPO associated vasculitis, respectively.
Interaction of ANCA with their target antigens
Binding of anti-PR3 to PR3 can inhibit the irreversible
inactivation of PR3 by a1-antitrypsin [49–51]. Binding of
anti-PR3 to PR3 may thus interfere with the clearance
of PR3, resulting in the longer persistence of anti-PR3-
PR3 complexes in tissues. The subsequent dissociation
of active PR3 from these complexes may then cause local
damage. The gene coding for a1-antitrypsin is highly
polymorphic, and more than 90 protein variants have
been identified. Severely deficient, medium, and nonde-
ficient proteinase inhibitor phenotypes can be distin-
guished. Interestingly, phenotypes associated with dys-
functional or with low serum levels of a1-antitrypsin are
Fig. 2. Superoxide release measured by ferricytochrome c reduction increased in patients with ANCA-positive vasculitis [138,
using tumor necrosis factor-a (TNF-a)–primed neutrophils from a 139] (abstract; Testa et al, Clin Exp Immunol 93(Suppl
healthy donor. Neutrophils were stimulated with immunoglobulin G
1):S16, 1993). Although the vast majority of ANCA-fractions from anti-PR3 (j, N 5 17) and anti-MPO–positive patients
(n, N 5 14) and from healthy controls (d, N 5 16). Immunoglobulin positive patients have normal a1-antitrypsin levels, these
G fractions from the ANCA-positive patients were obtained during data suggest that deficient a1-antitrypsin activity mayactive vasculitis prior to the start of immunosuppressive treatment.
predispose to ANCA associated vasculitis. Savige et alData are mean values 6 SEM. The dashed line indicates the release
of reactive oxygen radicals induced by fMLP. Reprinted from Franssen hypothesized that individuals with abnormal or deficient
et al [122]; used with permission from the American Society of Ne- a1-antitrypsin have reduced complexation of PR3 in se-
phrology.
rum and secretions, which may result in a PR3 molecule
in which the catalytic site is exposed and against which
auto-antibodies are produced in the appropriate immuno-
logic environment [139]. Two commonly known variantsCellular immune responses in
of the gene coding for a1-antitrypsin that are associatedANCA-associated vasculitis
with reduced a1-antitrypsin plasma levels are the Z alleleA role for cellular immune responses in ANCA-associ-
and the S allele. Griffith et al found that C-ANCA areated systemic vasculitis and NCGN is suggested by the
mainly associated with the Z allele of a1-antitrypsin andfrequent occurrence of respiratory tract granulomas,
P-ANCA mainly with the S allele [140]. Furthermore,consisting of mononuclear infiltrates with CD4-positive
Segelmark et al reported that anti-PR3–positive patientsT cells and monocytes [84]. CD4- and CD8-positive T
who are heterozygous for the Z allele have an enhancedcells, as well as monocytes, are also found in glomeruli
risk for dissemination of the vasculitic process and haveand the renal interstitium of patients with ANCA-associ-
a poorer prognosis [141].
ated NCGN (abstract; Brouwer et al, Kidney Int 39:1055–
Anti-MPO has been shown to disturb the inactivation
1056, 1991) [130]. Furthermore, relapses in patients with
of MPO by ceruloplasmin [38].
Wegener’s granulomatosis are associated with or pre-
ceded by a rise in levels of soluble markers of T-cell acti-
ANTI-PR3 OR ANTI-MPO: DOES IT REALLYvation such as soluble interleukin-2 receptor (IL-2R) [131,
MATTER FOR THE CLINICIAN?132] and soluble CD30 [133]. Recently, we have found
higher plasma levels of soluble CD30 in anti-PR3– than The recognition of clinical and histopathologic differ-
anti-MPO–positive patients with active NCGN [134]. ences between anti-PR3– and anti-MPO–positive pa-
Several in vitro studies have shown that peripheral blood tients with small-vessel vasculitis raises some important
mononuclear cells (PBMCs) from anti-PR3–positive pa- questions. Do differences between both groups also exist
tients proliferate on stimulation with PR3 [135–137]. In within the subcategories of small-vessel vasculitis? In
contrast, only one [137] of three studies [135–137] has other words, do anti-PR3–positive patients with Wegen-
reported T-cell proliferation in response to MPO in anti- er’s granulomatosis differ from anti-MPO–positive pa-
MPO–positive patients. These data suggest that T-cell tients with the same diagnosis? At present, it is difficult
reactivity may play a role in the pathophysiology of to answer this question. The diagnosis and classification
of patients by any classification system that is based onANCA-associated vasculitis. The difference in markers
Franssen et al: Anti-PR3– and anti-MPO–associated vasculitis2202
clinical and histopathologic criteria is dependent on the ings. Extrarenal organ manifestations and respiratory tract
granulomas occur more frequently in patients with anti-definitions used and on the policy to perform biopsies
of affected organs. The same patient may be either classi- PR3 than in those with anti-MPO. Anti-PR3–positive
patients with NCGN generally have a more dramaticfied as Wegener’s granulomatosis or as microscopic poly-
angiitis by different clinicians who use a different diag- deterioration of their renal function compared with anti-
MPO–positive patients. The term “ANCA-associated vas-nostic approach. In addition, the diagnosis may change
as the disease process evolves [88, 142]. Clearly, the culitis” is considered a useful concept in the presence of
ANCA specificity is less subject to debate or change. systemic vasculitis [145]. Likewise, in the presence of
Should we then use a classification system based on anti- vasculitis, the terms “anti-PR3–associated vasculitis” and
body type rather than on clinical and histopathologic “anti-MPO–associated vasculitis” are useful concepts.
criteria? Anti-PR3 and anti-MPO should not be used for
Reprint requests to Casper F.M. Franssen, M.D., Department of Inter-establishing a specific diagnosis. ANCA testing should, nal Medicine, Division of Nephrology, University Hospital Groningen,
however, be included in a rational investigative scheme Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
E-mail: c.f.m.franssen@int.azg.nl[143]. The diagnosis of patients with vasculitis depends
on the combination of clinical, histopathologic, and sero-
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